Present and future of acyclovir.
Acyclovir is now established as an effective and well tolerated therapeutic agent for the management of at least the more common infections of the herpes virus group. Evaluation of the drug nevertheless continues, primarily to verify its value in those infections caused by cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Furthermore with the development of analogues of acyclovir with better absorption profiles or enhanced anti-viral activity the future for this area of anti-viral therapy looks optimistic.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004660:Encephalitis / Q000188:drug therapy; D005544:Forecasting; D006509:Hepatitis B / Q000188:drug therapy; D006558:Herpes Genitalis / Q000188:drug therapy; D006560:Herpes Labialis / Q000188:drug therapy; D006561:Herpes Simplex / Q000150:complications; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D007108:Immune Tolerance; D007244:Infectious Mononucleosis / Q000188:drug therapy; D007635:Keratitis, Dendritic / Q000188:drug therapy; D012008:Recurrence
D000212:Acyclovir